Graphite Bio (GRPH) Stock Price, News & Analysis

Company Overview

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. The company offers GPH102 for the treatment of beta-thalassemia; and GPH201 for the treatment of XSCID, a life-threatening disease for multiple mutations in a single gene. It also offers GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is based in South San Francisco, California.

Key Stats

• Today's Range: $3.05 to $3.23
• 50-Day Range: $3.18 to $26.11
• 52-Week Range: $2.01 to $4.26
• Volume: 328,300 shs
• Average Volume: 282,405 shs
• Market Capitalization: $185.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GRPH Stock Analysis - Frequently Asked Questions

How were Graphite Bio's earnings last quarter?

Graphite Bio, Inc. (NASDAQ:GRPH) announced its earnings results on Monday, March, 20th. The company reported ($3.08) earnings per share for the quarter, beating analysts' consensus estimates of ($3.43) by $0.35.

When did Graphite Bio's stock split?

Shares of Graphite Bio reverse split before market open on Friday, March 22nd 2024. The 1-7 reverse split was announced on Friday, March 22nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

When did Graphite Bio IPO?

Graphite Bio (GRPH) raised $224 million in an initial public offering on Friday, June 25th 2021. The company issued 14,000,000 shares at $15.00-$17.00 per share.

What other stocks do shareholders of Graphite Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Graphite Bio investors own include Taiwan Semiconductor Manufacturing (TSM), Advanced Micro Devices (AMD), Carnival Co. & (CCL), Micron Technology (MU), PayPal (PYPL) and SoFi Technologies (SOFI).

Company Calendar

• Last Earnings: 3/20/2023
• Today: 3/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:GRPH
• CIK: 1815776
• Web: www.graphitebio.com
• Phone: 650-484-0886
• Fax: N/A
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-124,650,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -33.12%
• Return on Assets: -27.96%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 39.20
• Quick Ratio: 39.20

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.15 per share
• Price / Book: 1.01

Miscellaneous

• Outstanding Shares: 58,240,000
• Free Float: 35,874,000
• Market Cap: $185.20 million
• Optionable: Not Optionable
• Beta: 0.20